Immune diseases caused by mutations in kinases and components of the ubiquitin system

Nature Immunology

Volumn 15, Issue 6, 2014, Pages 521-529

  Cohen, Philip ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACT1 PROTEIN; BRUTON TYROSINE KINASE; I KAPPA B KINASE GAMMA; JANUS KINASE; OPTINEURIN; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PROTEIN KINASE; PROTEIN KINASE TBK1; PROTEIN KINASE ZAP 70; SALT INDUCIBLE KINASE; SEQUESTOSOME 1; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

DISEASE PREDISPOSITION; GENE MUTATION; GENETIC CODE; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN POLYMORPHISM; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; UBIQUITINATION;

HUMANS; IMMUNE SYSTEM DISEASES; MUTATION; PHOSPHORYLATION; PROTEIN KINASES; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84901016154     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.2892     Document Type: Review

References (128)

1. Husnjak, K. & Dikic, I. Ubiquitin-binding proteins: Decoders of ubiquitin-mediated cellular functions. Annu. Rev. Biochem. 81, 291-322 (2012
2. Smith, H. et al. Identification of the phosphorylation sites on the E3 ubiquitin ligase Pellino that are critical for activation by IRAK1 and IRAK4. Proc. Natl. Acad. Sci. USA 106, 4584-4590 (2009
3. Strack, P. et al. SCFβ-TRCP and phosphorylation dependent ubiquitination of IκBα catalyzed by Ubc3 and Ubc4. Oncogene 19, 3529-3536 (2000
4. Xia, Z.P. et al. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 461, 114-119 (2009
5. Cohen, P. & Alessi, D.R. Kinase drug discovery-what's next in the field?. ACS Chem. Biol. 8, 96-104 (2013
6. Cohen, P. & Tcherpakov, M. Will the ubiquitin system furnish as many drug targets as protein kinases?. Cell 143, 686-693 (2010
7. Emmerich, C.H. et al. Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains. Proc. Natl. Acad. Sci. USA 110, 15247-15252 (2013
8. Fiil, B.K. et al. OTULIN restricts Met1-linked ubiquitination to control innate immune signaling. Mol. Cell 50, 818-830 (2013
9. Clark, K., Nanda, S. & Cohen, P. Molecular control of the NEMO family of ubiquitin-binding proteins. Nat. Rev. Mol. Cell Biol. 14, 673-685 (2013
10. Courtois, G. & Israel, A. IKK regulation and human genetics. Curr. Top. Microbiol. Immunol. 349, 73-95 (2011
11. Döffinger, R. et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signaling. Nat. Genet. 27, 277-285 (2001
12. Ea, C.K., Deng, L., Xia, Z.P., Pineda, G. & Chen, Z.J. Activation of IKK by TNFα requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell 22, 245-257 (2006
13. Wu, C-J., Conze, D.B., Li, T., Srinivasula, S.M. & Ashwell, J.D. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-κB activation. Nat. Cell Biol. 8, 398-406 (2006
14. Kensche, T. et al. Analysis of nuclear factor-κB (NF-κB) essential modulator (NEMO) binding to linear and lysine-linked ubiquitin chains and its role in the activation of NF-κB. J. Biol. Chem. 287, 23626-23634 (2012
15. Lo, Y.C. et al. Structural basis for recognition of diubiquitins by NEMO. Mol. Cell 33, 602-615 (2009
16. Picard, C., Casanova, J.L. & Puel, A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBα deficiency. Clin. Microbiol. Rev. 24, 490-497 (2011
17. Kirisako, T. et al. A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J. 25, 4877-4887 (2006
18. Boisson, B. et al. Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nat. Immunol. 13, 1178-1186 (2012
19. HogenEsch, H., Janke, S., Boggess, D. & Sundberg, J.P. Absence of Peyer's patches and abnormal lymphoid architecture in chronic proliferative dermatitis (cpdm/cpdm) mice. J. Immunol. 162, 3890-3896 (1999
20. Gerlach, B. et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 471, 591-596 (2011
21. Ikeda, F. et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis. Nature 471, 637-641 (2011
22. Rigaud, S. et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444, 110-114 (2006
23. Damgaard, R.B. et al. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol. Cell 46, 746-758 (2012
24. Damgaard, R.B. et al. Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling. EMBO Mol. Med. 5, 1278-1295 (2013
25. Philpott, D.J., Sorbara, M.T., Robertson, S.J., Croitoru, K. & Girardin, S.E. NOD proteins: Regulators of inflammation in health and disease. Nat. Rev. Immunol. 14, 9-23 (2014
26. Schwandner, R., Yamaguchi, K. & Cao, Z. Requirement of tumor necrosis factor receptor-Associated factor (TRAF)6 in interleukin 17 signal transduction. J. Exp. Med. 191, 1233-1240 (2000
27. Liu, C. et al. Act1, a U-box E3 ubiquitin ligase for IL-17 signaling. Sci. Signal. 2, ra63 (2009
28. Qian, Y. et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat. Immunol. 8, 247-256 (2007
29. Boisson, B. et al. An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity 39, 676-686 (2013
30. Conti, H.R. et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J. Exp. Med. 206, 299-311 (2009
31. Iwakura, Y. & Ishigame, H. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 116, 1218-1222 (2006
32. Park, H. et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6, 1133-1141 (2005
33. Gleason, C.E., Ordureau, A., Gourlay, R., Arthur, J.S. & Cohen, P. Polyubiquitin binding to optineurin is required for optimal activation of TANK-binding kinase 1 and production of interferon β. J. Biol. Chem. 286, 35663-35674 (2011
34. Wild, P. et al. Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth. Science 333, 228-233 (2011
35. Morton, S., Hesson, L., Peggie, M. & Cohen, P. Enhanced binding of TBK1 by an optineurin mutant that causes a familial form of primary open angle glaucoma. FEBS Lett. 582, 997-1002 (2008
36. Munitic, I. et al. Optineurin insufficiency impairs IRF3 but not NF-κB activation in immune cells. J. Immunol. 191, 6231-6240 (2013
37. Pilli, M. et al. TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation. Immunity 37, 223-234 (2012
38. Albagha, O.M. et al. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nat. Genet. 42, 520-524 (2010
39. Laurin, N., Brown, J.P., Morissette, J. & Raymond, V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am. J. Hum. Genet. 70, 1582-1588 (2002
40. Maruyama, H. et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465, 223-226 (2010
41. Rubino, E. et al. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology 79, 1556-1562 (2012
42. Rezaie, T. et al. Adult-onset primary open-Angle glaucoma caused by mutations in optineurin. Science 295, 1077-1079 (2002
43. Kawase, K. et al. Confirmation of TBK1 duplication in normal tension glaucoma. Exp. Eye Res. 96, 178-180 (2012
44. Nanda, S.K. et al. Polyubiquitin binding to ABIN1 is required to prevent autoimmunity. J. Exp. Med. 208, 1215-1228 (2011
45. Gregersen, P.K. et al. Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08. Ann. Neurol. 72, 927-935 (2012
46. Han, J.W. et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat. Genet. 41, 1234-1237 (2009
47. He, C.F. et al. TNIP1, SLC15A4, ETS1, RasGRP3 and IKZF1 are associated with clinical features of systemic lupus erythematosus in a Chinese Han population. Lupus 19, 1181-1186 (2010
48. Nair, R.P. et al. Psoriasis bench to bedside: Genetics meets immunology. Arch. Dermatol. 145, 462-464 (2009
49. Yang, Q. et al. Investigation of 20 non-HLA (human leucocyte antigen) psoriasis susceptibility loci in Chinese patients with psoriatic arthritis and psoriasis vulgaris. Br. J. Dermatol. 168, 1060-1065 (2013
50. Caster, D.J. et al. ABIN1 dysfunction as a genetic basis for lupus nephritis. J. Am. Soc. Nephrol. 24, 1743-1754 (2013
51. Matmati, M. et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat. Genet. 43, 908-912 (2011
52. Skaug, B. et al. Direct, noncatalytic mechanism of IKK inhibition by A20. Mol. Cell 44, 559-571 (2011
53. Tokunaga, F. et al. Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-κB regulation. EMBO J. 31, 3856-3870 (2012
54. Verhelst, K. et al. A20 inhibits LUBAC-mediated NF-κB activation by binding linear polyubiquitin chains via its zinc finger 7. EMBO J. 31, 3845-3855 (2012
55. Ngo, V.N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115-119 (2011
56. Nocturne, G. et al. Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome. Blood 122, 4068-4076 (2013
57. Dong, G. et al. A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma. Clin. Cancer Res. 17, 1440-1451 (2011
58. Wertz, I.E. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430, 694-699 (2004
59. Komander, D. et al. Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep. 10, 466-473 (2009
60. Lu, T.T. et al. Dimerization and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme. Immunity 38, 896-905 (2013
61. Haglund, K. & Dikic, I. The role of ubiquitylation in receptor endocytosis and endosomal sorting. J. Cell Sci. 125, 265-275 (2012
62. Katoh, Y. et al. Tollip and Tom1 form a complex and recruit ubiquitin-conjugated proteins onto early endosomes. J. Biol. Chem. 279, 24435-24443 (2004
63. Burns, K. et al. Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat. Cell Biol. 2, 346-351 (2000
64. Zhang, G. & Ghosh, S. Negative regulation of toll-like receptor-mediated signaling by Tollip. J. Biol. Chem. 277, 7059-7065 (2002
65. Brissoni, B. et al. Intracellular trafficking of interleukin-1 receptor I requires Tollip. Curr. Biol. 16, 2265-2270 (2006
66. Bulut, Y., Faure, E., Thomas, L., Equils, O. & Arditi, M. Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: Role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J. Immunol. 167, 987-994 (2001
67. Didierlaurent, A. et al. Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide. Mol. Cell. Biol. 26, 735-742 (2006
68. Shah, J.A. et al. Human TOLLIP regulates TLR2 and TLR4 signaling and its polymorphisms are associated with susceptibility to tuberculosis. J. Immunol. 189, 1737-1746 (2012
69. Mira, M.T. et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 427, 636-640 (2004
70. de Leseleuc, L. et al. PARK2 mediates interleukin 6 and monocyte chemoattractant protein 1 production by human macrophages. PLoS Negl. Trop. Dis. 7, e2015 (2013
71. Hasan, Z. et al. Elevated serum CCL2 concomitant with a reduced mycobacterium-induced response leads to disease dissemination in leprosy. Scand. J. Immunol. 63, 241-247 (2006
72. Keusekotten, K. et al. OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin. Cell 153, 1312-1326 (2013
73. Jin, W. et al. Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J. Clin. Invest. 118, 1858-1866 (2008
74. Jin, W. et al. Deubiquitinating enzyme CYLD regulates the peripheral development and naive phenotype maintenance of B cells. J. Biol. Chem. 282, 15884-15893 (2007
75. Reiley, W.W. et al. Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat. Immunol. 7, 411-417 (2006
76. Zhang, M. et al. Regulation of IκB kinase-related kinases and antiviral responses by tumor suppressor CYLD. J. Biol. Chem. 283, 18621-18626 (2008
77. Sun, S.C. CYLD: A tumor suppressor deubiquitinase regulating NF-κB activation and diverse biological processes. Cell Death Differ. 17, 25-34 (2010
78. Rivkin, E. et al. The linear ubiquitin-specific deubiquitinase gumby regulates angiogenesis. Nature 498, 318-324 (2013
79. Lin, S.C., Lo, Y.C. & Wu, H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 465, 885-890 (2010
80. Motshwene, P.G. et al. An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4. J. Biol. Chem. 284, 25404-25411 (2009
81. Picard, C. et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299, 2076-2079 (2003
82. Picard, C. et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore) 89, 403-425 (2010
83. Baxter, E.J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061 (2005
84. Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790 (2005
85. Laurence, A., Pesu, M., Silvennoinen, O. & O'Shea, J. JAK kinases in health and disease: An update. Open Rheumatol. J. 6, 232-244 (2012
86. Macchi, P. et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377, 65-68 (1995
87. Russell, S.M. et al. Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development. Science 270, 797-800 (1995
88. Rochman, Y., Spolski, R. & Leonard, W.J. New insights into the regulation of T cells by γc family cytokines. Nat. Rev. Immunol. 9, 480-490 (2009
89. Minegishi, Y. et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25, 745-755 (2006
90. Watford, W.T. & O'Shea, J.J. Human tyk2 kinase deficiency: Another primary immunodeficiency syndrome. Immunity 25, 695-697 (2006
91. Li, Z. et al. Two rare disease-Associated Tyk2 variants are catalytically impaired but signaling competent. J. Immunol. 190, 2335-2344 (2013
92. Eyre, S. et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat. Genet. 44, 1336-1340 (2012
93. Conley, M.E., Mathias, D., Treadaway, J., Minegishi, Y. & Rohrer, J. Mutations in Btk in patients with presumed X-linked agammaglobulinemia. Am. J. Hum. Genet. 62, 1034-1043 (1998
94. Holinski-Feder, E. et al. Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 unique mutations without correlation to clinical course. Pediatrics 101, 276-284 (1998
95. Tsukada, S. et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72, 279-290 (1993
96. Vetrie, D. et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-Tyrosine kinases. Nature 361, 226-233 (1993
97. Fischer, A. et al. ZAP70: A master regulator of adaptive immunity. Semin. Immunopathol. 32, 107-116 (2010
98. Arpaia, E., Shahar, M., Dadi, H., Cohen, A. & Roifman, C.M. Defective T cell receptor signaling and CD8+ thymic selection in humans lacking zap-70 kinase. Cell 76, 947-958 (1994
99. Chan, A.C. et al. ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency. Science 264, 1599-1601 (1994
100. Picard, C. et al. Hypomorphic mutation of ZAP70 in human results in a late onset immunodeficiency and no autoimmunity. Eur. J. Immunol. 39, 1966-1976 (2009
101. Sakaguchi, N. et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426, 454-460 (2003
102. Aguado, E. et al. Induction of T helper type 2 immunity by a point mutation in the LAT adaptor. Science 296, 2036-2040 (2002
103. Sommers, C.L. et al. A LAT mutation that inhibits T cell development yet induces lymphoproliferation. Science 296, 2040-2043 (2002
104. Sancho-Shimizu, V. et al. Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J. Clin. Invest. 121, 4889-4902 (2011
105. Zhang, S.Y. et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 317, 1522-1527 (2007
106. Herman, M. et al. Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J. Exp. Med. 209, 1567-1582 (2012
107. Okkenhaug, K. & Vanhaesebroeck, B. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 3, 317-330 (2003
108. Lucas, C.L. et al. Dominant-Activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat. Immunol. 15, 88-97 (2014
109. Angulo, I. et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science 342, 866-871 (2013
110. Bleich, A. et al. Cdcs1 a major colitis susceptibility locus in mice; subcongenic analysis reveals genetic complexity. Inflamm. Bowel Dis. 16, 765-775 (2010
111. Boulard, O., Kirchberger, S., Royston, D.J., Maloy, K.J. & Powrie, F.M. Identification of a genetic locus controlling bacteria-driven colitis and associated cancer through effects on innate inflammation. J. Exp. Med. 209, 1309-1324 (2012
112. Cho, J.H. The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol. 8, 458-466 (2008
113. Cho, J.H. et al. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: Evidence for epistasis between 1p and IBD1. Proc. Natl. Acad. Sci. USA 95, 7502-7507 (1998
114. Heine, M. et al. α-kinase 1, a new component in apical protein transport. J. Biol. Chem. 280, 25637-25643 (2005
115. Kay, J.G., Murray, R.Z., Pagan, J.K. & Stow, J.L. Cytokine secretion via cholesterol-rich lipid raft-Associated SNAREs at the phagocytic cup. J. Biol. Chem. 281, 11949-11954 (2006
116. Luo, C., Wang, K., Liu, D., Li, Y. & Zhao, Q.S. The functional roles of lipid rafts in T cell activation, immune diseases and HIV infection and prevention. Cell. Mol. Immunol. 5, 1-7 (2008
117. Wang, S.J. et al. Lymphocyte α-kinase is a gout-susceptible gene involved in monosodium urate monohydrate-induced inflammatory responses. J. Mol. Med. (Berl.) 89, 1241-1251 (2011
118. Pauls, E. et al. Two phases of inflammatory mediator production defined by the study of IRAK2 and IRAK1 knock-in mice. J. Immunol. 191, 2717-2730 (2013
119. Uematsu, S. et al. Interleukin-1 receptor-Associated kinase-1 plays an essential role for Toll-like receptor (TLR)7-And TLR9-mediated interferon-α induction. J. Exp. Med. 201, 915-923 (2005
120. Barrat, F.J. et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202, 1131-1139 (2005
121. Jacob, C.O. et al. Identification of novel susceptibility genes in childhood-onset systemic lupus erythematosus using a uniquely designed candidate gene pathway platform. Arthritis Rheum. 56, 4164-4173 (2007
122. Jacob, C.O. et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 106, 6256-6261 (2009
123. Clark, K. et al. Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc. Natl. Acad. Sci. USA 109, 16986-16991 (2012
124. MacKenzie, K.F. et al. PGE2 induces macrophage IL-10 production and a regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway. J. Immunol. 190, 565-577 (2013
125. Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119-124 (2012
126. Liu, J.Z. et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat. Genet. 45, 670-675 (2013
127. Graham, R.R. et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus (SLE). Nat. Genet. 40, 1059-1061 (2008
128. Musone, S.L. et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat. Genet. 40, 1062-1064 (2008